论文部分内容阅读
目的 :明确雾化液吸入方式对慢性阻塞性肺病 (COPD)支气管扩张剂量反应。方法 :采用随机、单盲交叉试验 ,对 3 3例稳定期COPD患者于 6个治疗日分别气道雾化液吸入 0 .0 5 ,0 .1,0 .2 ,0 .4 ,0 .6mg异丙托溴铵及安慰剂 ,最后定量雾化吸入器吸入 2 0 μg异丙托溴铵 ,观察用药后 8h一秒钟用力呼气量 (FEV1)变化。结果 :0 .4mg及 0 .6mg异丙托溴铵对FEV1以及其曲线下面积的增加作用都较其他剂量明显 ,但无显著差异 (P >0 .0 5 ) ;定量雾化吸入器吸入 2 0 μg相当于雾化液吸入 0 .0 8mg的强度。 8h内所有剂量对FEV1的作用都明显大于安慰剂 (P <0 .0 1)。结论 :异丙托溴铵对稳定期COPD患者雾化液吸入治疗最佳剂量为 0 .4mg ,定量雾化吸入器吸入 2 0 μg相当于雾化液吸入 0 .0 8mg的支气管扩张效果
OBJECTIVE: To clarify the dose response of aerosol inhalation to bronchiectasis in patients with chronic obstructive pulmonary disease (COPD). Methods: A randomized, single-blind crossover study was performed on 33 patients with stable COPD who received inhaled airway fluid for 0, 0.5, 0.1, 0.2, 0.4, 0.6 mg Ipratropium bromide and placebo, the last quantitative inhaler inhalation of 20mg ipratropium bromide, observed after 8h forced expiratory volume one second (FEV1) changes. Results: The effects of 0. 4mg and 0. 6mg ipratropium bromide on FEV 1 and the area under the curve were significantly higher than those at other doses, but no significant difference (P> 0. 05) 0 μg corresponds to an intensity of 0.08 mg inhaled by the nebulizer. All doses within 8 h had a significantly greater effect on FEV1 than placebo (P <0.01). Conclusion: The optimal dose of ipratropium bromide inhalation for patients with stable COPD was 0. 4 mg, inhalation of 20 μg with the inhalation of the quantitative nebulizer corresponded to 0.08 mg bronchodilator inhalation